Skip to Content
  • Previous Rank
    9
  • Revenue 3 Yr Annual Growth Rate
    59%
  • Revenue 3 Yr Growth Rank
    9
  • EPS 3 Yr Annual Growth Rate
    112%
  • EPS 3 Yr Growth Rank
    13
  • Total Return 3 Yr Annual Rate
    19%
  • Total Return 3 Yr Rank
    66

Revenues from new (and safer) HIV meds, including Descovy, Genvoya, and Odefsey, are soothing a drop-off in this biopharma company’s hepatitis C drug sales.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

Location
Foster City, Calif.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak2
Years on List7
CEO
John Milligan
Websitehttp://www.gilead.com
Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$32,839
Net Income Past Four Quarters ($M)$17,341

Growth Rates and Ranks

Revenue 3 Yr Growth Rank9
EPS 3 Yr Annual Growth Rate112%
EPS 3 Yr Growth Rank13
Total Return 3 Yr Annual Rate19%
Total Return 3 Yr Rank
66